David Walk, MD
Neuromuscular Medicine · Minneapolis, MNNPI 1679674501
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $34,923 of the $36,885 with a category attached, or 94.7%. Tanabe Pharma America, Inc. accounts for 90.4% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2022 at $15,440 and has fallen 99.6% since, to $59 in 2024.
Across 35 payments — averaging $1053.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tanabe Pharma America, Inc.$33K
- Biogen$3K
- Sarepta Therapeutics, Inc.$370
- Argenx US, Inc.$59
- Natus Medical Incorporated$45
Across 6 payments — averaging $2649.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$13K
- Biohaven Pharmaceutical Holding Company Ltd.$3K
What the payments were for
- Consulting fees$34,92395%
- Travel & lodging$1,2523%
- Food & beverage$7112%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tanabe Pharma America, Inc. | 31 | $33,347 |
| Biogen | 1 | $3,065 |
| Sarepta Therapeutics, Inc. | 1 | $370 |
| Argenx US, Inc. | 1 | $59 |
| Natus Medical Incorporated | 1 | $45 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Radicava$32,780
- EXSERVAN$1,100
- Radicava ORS$1,100
- Exondys 51$370
How this compares
Too few neuromuscular medicine providers in Minnesotato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Radicava OrsEdaravone | 109 | $1,573,814 |
| FirdapseAmifampridine Phosphate | 19 | $725,966 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 52 | $451,529 |
| NuedextaDextromethorphan Hbr/Quinidine | 17 | $26,857 |
| Riluzole | 75 | $13,314 |
| Gabapentin | 61 | $1,781 |
| Mycophenolate Mofetil | 13 | $1,052 |
| Azathioprine | 17 | $588 |
| Glycopyrrolate | 17 | $562 |
| Pyridostigmine Bromide | 11 | $427 |
| Mirtazapine | 24 | $393 |
| Tizanidine Hcl | 13 | $380 |
| Pregabalin | 11 | $339 |
| Prednisone | 48 | $268 |
| Duloxetine Hcl | 21 | $246 |
Paid to pharmacies, not to this prescriber.
Other neuromuscular medicine in Minneapolis
- Elie NaddafRochester$15K
- Pitcha ChompoopongRochester$12K
- Abhi MunshiSt. Louis Park$118
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.